ClinicalTrials.gg
RecruitingNCT05779644Updated May 16, 2023

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

An interventional study of Liraglutide and Semaglutide in Metformin, Obesity, Abdominal and Diabetes Mellitus, Type 2, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Obesity, Abdominal with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Obesity, Abdominal · China.

Planned enrollment
5th of 17
300 · median 120
Started
2023
with 2 others
No phase
12 of 19
5 open now
Registered
12th of 19
by date

Among the 19 studies in Obesity, Abdominal with a site in China, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 12th registered.

Obesity, Abdominal

295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.

Browse Obesity, Abdominal studies →

Open to participants now

6 of the 19 studies in Obesity, Abdominal with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Obesity, Abdominal with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Read the detailed description

Specific research contents: To study the characteristics of glucose and lipid metabolism and fat distribution in overweight/obesity patients with type 2 diabetes mellitus; liraglutide/ semaglutide/ metformin will be applied to patients for one year, and the changes of lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes and the differences among the three groups will be analyzed before and after treatment. The metabolomic changes of overweight/obese patients with type 2 diabetes before and after medication and the differences among the three groups will be analyzed. Explore the correlation between visceral fat content, glucose and lipid metabolism, inflammatory factors and other biochemical indicators and metabolomics.

03

Conditions studied

  • Metformin
  • Obesity, Abdominal
  • Diabetes Mellitus, Type 2
  • Abdominal Fat
  • Non-Alcoholic Fatty Liver Disease
  • Metabolism Disorder, Glucose
  • Metabolism Disorder, Lipid

Keywords

  • Metformin
  • Glucagon-Like Peptide-1 Receptor
  • Obesity, Abdominal
  • Diabetes Mellitus, Type 2
  • Non-Alcoholic Fatty Liver Disease
  • Metabolism Disorder, Glucose
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years old
  • ≥24kg/㎡, or waist circumference: > 85cm (for male) or > 80cm (for female)
  • Has been diagnosed with type 2 diabetes mellitus
  • Good blood glucose control in recent three months: random blood sugar \< 14mmol/L and 6-9%
  • Not received any drugs affecting glucose and lipid metabolism or weight loss surgery in the past one month

Exclusion criteria

Exclusion Criteria:

  • Abnormal weight gain caused by other endocrine diseases
  • Severe metabolic diseases, such as diabetic ketoacidosis, hypertonic hyperglycemia
  • Type 1 diabetes or other special types of diabetes
  • Used drugs affecting glycolipid metabolism in the past three months
  • Severe bleeding tendency that unable to complete venous blood collection
  • Patients with MRI
  • Severe renal insufficiency or severe liver insufficiency
  • Patients with advanced malignant tumors
  • Serious cardiovascular and cerebrovascular diseases
  • Rheumatic and immune diseases
  • Pregnant and lactating women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Liraglutide group

    Liraglutide is injected once a day.

    Drug: Liraglutide

  • Experimental
    Semaglutide group

    Semaglutide is injected once a week.

    Drug: Semaglutide

  • Experimental
    Metformin group

    Metformin is taken orally daily.

    Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Blood glucose

    Glucose metabolism index

    Time frame: The twelfth week of treatment

  2. Blood insulin

    Glucose metabolism index

    Time frame: The twelfth week of treatment

  3. Total cholesterol

    Lipid metabolism index

    Time frame: The twelfth week of treatment

  4. Triglyceride

    Lipid metabolism index

    Time frame: The twelfth week of treatment

  5. Lipoprotein

    Lipid metabolism index

    Time frame: The twelfth week of treatment

  6. Weight

    Measure fasting weight

    Time frame: The twelfth week of treatment

  7. Abdominal fat distribution

    Use Magnetic resonance imaging-proton density fat fraction to measure fat accumulation in the liver, pancreas and abdomen.

    Time frame: The twelfth week of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2025, 24 months after the start.

Of 107 non-industry interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 24 months is above that.

Counting every sponsor, half of 117 studies reached it within 16 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Mar 22, 2023
StartActual
Feb 23, 2023
Primary completionEst.
Feb 23, 2025
CompletionEst.
Feb 23, 2025
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05779644
Lead sponsor
RenJi Hospital
Responsible party
Jing Ma (Head of Endocrinology and Metabolism, RenJi Hospital) — Principal investigator
First posted
Mar 22, 2023
Start date
Feb 23, 2023
Primary completion
Feb 23, 2025 (estimated)
Completion
Feb 23, 2025 (estimated)
Last update
May 16, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liraglutide · Semaglutide · Metformin

Start the discussion